NCT02705105已完成1 期
Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 114
- 试验地点
- 15
- 主要终点
- Maximum Tolerated Dose (MTD)
研究概览
简要总结
The purpose of this study is to characterize the safety and tolerability and determine the maximum tolerated dose (MTD) or the recommended fixed dose of the combinations of mogamulizumab and nivolumab in subjects with locally advanced or metastatic solid tumors.
详细描述
This is a multicenter, Phase 1/2 open-label, dose-finding and cohort expansion study of the anti-CCR4 antibody mogamulizumab in combination therapy with the anti-PD-1 antibody nivolumab in adult subjects with locally advanced or metastatic solid tumors.
Phase 1 will identify the maximum tolerated dose (MTD) or the highest protocol-defined dose in absence of exceeding the MTD, of the combination regimen of mogamulizumab and nivolumab subjects. Phase 1 will enroll up to 12 subjects. Phase 2 will explore the safety, efficacy and anti-tumor activity of the highest tolerated dose of the combination regimen. Phase 2 will enroll up to 184 subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed hepatocellular carcinoma not amenable for management with curative intent by surgery or local therapeutic measure;
- •Subject must have received sorafenib treatment and either:
- •have had documented radiographic or symptomatic progression during or after sorafenib therapy; OR
- •be intolerant of sorafenib (defined as Grade 2 drug-related adverse event which 1) persisted in spite of comprehensive supportive therapy according to institutional standards AND 2) persisted or recurred after sorafenib treatment interruption of at least 7 days and dose reduction by one dose level (to 400 mg once daily) AND/OR Grade 3 drug-related adverse event which 1) persisted in spite of comprehensive supportive therapy according to institutional standards OR 2) persisted or recurred after sorafenib treatment interruption of at least 7 days and dose reduction by one dose level (to 400 mg once daily); OR must have documented refusal of sorafenib;
- •Subject has Child-Pugh score of ≤6, i.e., Child-Pugh A (Appendix 2);
- •INR ≤ 2.3 or Prothrombin time (PT) ≤ 6 seconds above control;
- •Subject has HBV DNA viral load undetectable or < 100 IU/mL at screening. If subject has detectable HBsAg, HBeAg, or HBV DNA (indicating ongoing viral replication of hepatitis B, he/she must be on antiviral therapy per regional standard of care guidelines prior to initiation of study therapy. If not on antiviral therapy at screening, then the subject must initiate treatment per regional standard of care guidelines prior to C1D1 and must be willing to continue antiviral therapy while on study treatment.
- •Exclusion Criteria
- •Female subject who is pregnant or breast-feeding, or any subject expecting to conceive or father a child during this study;
- •Subjects with uncontrolled and significant inter-current illness.
- •Subjects has psychiatric illness/social situations that in the opinion of the investigator would limit compliance with study requirements;
- •Subject has primary central nervous system (CNS) tumor or known CNS metastases and/or history of CNS metastases and/or carcinomatous meningitis; Exception: Subjects are eligible if CNS metastases are adequately treated and subjects are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 4 weeks prior to enrollment. In addition, subjects must be off corticosteroids for 4 weeks prior to enrollment.
- •Subject has received prior therapy for cancer or major surgery within 28 days, or 42 days for nitrosourea or mitomycin C, prior to Cycle 1 Day 1, or 14 days for tamoxifen;
- •Subject has received radiotherapy or radiosurgery within 14 days prior to Cycle 1 Day 1;
- •Subject has been previously treated with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways;
- •Subject has been previously treated with mogamulizumab;
- •Subject has a history of allergy or hypersensitivity to study drug components;
- •Subject has received a live, attenuated vaccine within 28 days prior to Cycle 1 Day 1;
- •Subject has a history of organ transplant or allogeneic bone marrow transplant;
- •Subject has any unresolved toxicity Grade > 1 from previous anti-cancer therapy
- •Subject use of immunosuppressive medication within 14 days before Cycle 1 Day
- •Subjects who have known active autoimmune disease or a history of autoimmune disease which may affect vital organ function or require immune suppressive treatment including systemic corticosteroids;
- •Subjects who have history of toxic epidermal necrolysis or Stevens-Johnson syndrome;
- •Subjects who have a history of inflammatory bowel disease, Crohn's disease, ulcerative colitis, or Wegener's granulomatosis;
- •Subject has primary or acquired immunodeficiency or known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome;
- •Subject who tests positive for hepatitis B surface antigen (HBVsAg) or hepatitis C RNA indicating acute or chronic infection except for subjects with hepatocellular carcinoma;
- •Subject has another active malignancy requiring concurrent intervention;
- •Subject who is receiving any other investigational agents;
- •Subject has another condition that, in the opinion of the Investigator and/or Sponsor, would interfere with evaluation of the IMP or interpretation of subject safety or study results;
- •Subject has a history of pneumonitis or interstitial lung disease.
- •Hepatocellular Carcinoma Exclusion Criterion:
- •Any history of hepatic encephalopathy
- •Any prior (within 1 year) or current clinically significant ascites as measured by physical examination and that requires paracentesis for control;
- •Active coinfection with both hepatitis B (i.e., HBVsAg and/or hepatitis B DNA) and hepatitis C (i.e., hepatitic C RNA)
- •Hepatitis D infection in subjects with hepatitis B
- •Any history of clinically meaningful variceal bleeding within the last three months.
排除标准
- 未提供
结局指标
主要结局
Maximum Tolerated Dose (MTD)
时间窗: From the first dose of study medications until 14 days after the last dose of study medication
The MTD was defined as one dose level below the dose level of the cohort where ≥ one-third of the subjects experienced a dose-limiting toxicity (DLT)
Number of Subjects Experiencing Dose-limiting Toxicity
时间窗: From the first dose of study medications until 14 days after the last dose of study medication
combination of mogamulizumab and nivolumab
次要结局
- Objective Tumor Response Rate According to RECIST(From baseline to every 12 weeks, until data cut off)
研究者
研究点 (15)
Loading locations...
相似试验
进行中（未招募）
2 期
Mogamulizumab Q4week Dosing in Participants With R/R CTCLCutaneous T-Cell Lymphoma, RelapsedCutaneous T-Cell Lymphoma RefractoryNCT04745234Kyowa Kirin, Inc.34
Unknown
1 期
A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C MutationAdvanced Solid TumorNCT05119933Shanghai YingLi Pharmaceutical Co. Ltd.55
已完成
2 期
Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Participants With Chronic HCV Infection and Child-Pugh-Turcotte Class C CirrhosisHepatitis C Virus InfectionNCT02994056Gilead Sciences32
已完成
2 期
Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal DiseaseHepatitis C Virus InfectionNCT03036839Gilead Sciences95
已完成
2 期
Sofosbuvir/Velpatasvir in Adults With Chronic Hepatitis C Virus Infection Who Are on Dialysis for End Stage Renal DiseaseChronic Hepatitis CNCT03036852Gilead Sciences59